{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-011528","form_type":"8-K","ticker":null,"cik":"0000810509","company_name":"NAVIDEA BIOPHARMACEUTICALS, INC.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.320212+00:00","generated_at":"2026-06-16T07:09:14.505909+00:00","sec_items":["2.03","1.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Navidea secures up to $10.75M via milestone sale, equity line, and bridge note","bullets":["LOI to sell Cardinal milestone payment (due when Lymphoseek sales exceed $100M) for $8M.","Entered $2.75M common stock purchase agreement with Keystone; 400K commitment shares issued.","Received $225K advance under $300K secured bridge note from Vice Chairman John K. Scott Jr.","Proceeds to fund Phase IIb (NAV3-32) and Phase III (NAV3-33) trials and working capital.","Bridge note matures June 26, 2023; secured by all company assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-011528","json":"https://secwatch.observer/filing/0001437749-23-011528.json","markdown":"https://secwatch.observer/filing/0001437749-23-011528.md","text":"https://secwatch.observer/filing/0001437749-23-011528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/810509/000143774923011528/0001437749-23-011528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/810509/000143774923011528/navb20230427_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T07:09:14.505909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b5f21d884e5aa8d4da6655ca9221bb5d13ab9b4","claim":"NAVIDEA BIOPHARMACEUTICALS, INC. incurred loan of up to $300,000 with John K. Scott, Jr. maturing June 26, 2023.","evidence_excerpt":"On April 25, 2023, John K. Scott, Jr., the current Vice Chairman of the Board, agreed to makes advances to the Company in the aggregate principal amount of up to $300,000 under the terms of a secured bridge note (the “2023 Bridge Note”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/810509/000143774923011528/0001437749-23-011528-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $300,000"},{"label":"Counterparty","value":"John K. Scott, Jr."},{"label":"Maturity","value":"June 26, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}